Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2026)

Catalyst Pharmaceuticals filings provide 9 years of EBT Margin readings, the most recent being 56.38% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 598.0% to 56.38% in Q1 2026 year-over-year; TTM through Mar 2026 was 49.66%, a 132.0% increase, with the full-year FY2025 number at 48.14%, up 416.0% from a year prior.
  • EBT Margin hit 56.38% in Q1 2026 for Catalyst Pharmaceuticals, up from 47.11% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 56.38% in Q1 2026 to a low of 37.03% in Q3 2023.
  • Median EBT Margin over the past 5 years was 47.11% (2025), compared with a mean of 41.88%.
  • Biggest five-year swings in EBT Margin: plummeted -8246bps in 2023 and later surged 8148bps in 2024.
  • Catalyst Pharmaceuticals' EBT Margin stood at 54.33% in 2022, then fell by -22bps to 42.24% in 2023, then increased by 24bps to 52.31% in 2024, then dropped by -10bps to 47.11% in 2025, then increased by 20bps to 56.38% in 2026.
  • The last three reported values for EBT Margin were 56.38% (Q1 2026), 47.11% (Q4 2025), and 47.87% (Q3 2025) per Business Quant data.